Making the discoveries that defeat cancer

  • Home »
  • Research »
  • Repository

  • Administrators Login

  • Repository Homepage
  • About the Repository
  • Browse the Repository
  • Search the Repository
  • Contribute an Article
  • Missing Publications
  • Repository Help

BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-Ribose) polymerase

Tools
- Tools
+ Tools

McCabe, N., Lord, C. J., Tutt, A. N. J., Martin, N. M. B., Smith, G. C. M., Ashworth, A. (2005) BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-Ribose) polymerase. CANCER BIOLOGY & THERAPY, 4 (9). pp. 934-936. ISSN 1538-4047

Full text not available from this repository.

A copy of the full text may be available at: http://www.landesbioscience.com/journals/cbt/artic...

Abstract

BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-Ribose) polymerase We have previously demonstrated that deficiency of either the BRCA1 or BRCA2 breast cancer susceptibility proteins confers substantial cellular sensitivity to the inhibition of Poly(ADP-Ribose) polymerase ( PARP). PARP is a key enzyme in the repair of single strand DNA damage via the Base Excision Repair pathway. We suggested that PARP inhibition produces persistent single-strand DNA breaks or gaps which degenerate into stalled replication forks and double-strand breaks, which may be repaired by homologous recombination, a process partially dependent on BRCA1 and BRCA2. It has recently been suggested that our results might be limited to certain BRCA2 mutations as the CAPAN-1 cell line, which carries a naturally occurring 6174delT mutation in one BRCA2 allele accompanied by loss of the wild-type allele, is apparently insensitive to two PARP inhibitors 3-aminobenzamide (IC50 33 mu M) and NU1025 (IC50 400 nM). Here we show that CAPAN-1 cells are in fact very sensitive to the potent PARP inhibitors KU0058684 (IC50 3.2 nM) and KU0058948 (IC50 3.4 nM). In contrast, our results reveal much less sensitivity to a chemically related but much less active compound KU0051529 (IC50 730 nM) and to NU1025. These results confirm that treatment with potent PARP inhibitors remains an exciting potential therapy for cancers involving BRCA1 or BRCA2 deficiency.

Item Type: Article
Authors (ICR Faculty only): Ashworth, Alan and Lord, Chris
All Authors: McCabe, N., Lord, C. J., Tutt, A. N. J., Martin, N. M. B., Smith, G. C. M., Ashworth, A.
Uncontrolled Keywords: BRCA2; breast cancer; poly (ADP-Ribose); polymerase; potency; drug sensitivity Dna-repair defect; poly(adp-ribose) polymerase; replication; recombination; maintenance; cancer; tumors
Research teams: ICR divisions > Breast Cancer Research > Gene Function
ICR divisions > Molecular Pathology > Gene Function
Depositing User: EPrints Services
Date Deposited: 10 Aug 2007 20:53
Last Modified: 10 Feb 2010 11:46
URI: http://publications.icr.ac.uk/id/eprint/2402

Actions (login required)

View Item View Item
The Royal Marsden - NHS foundation trust